Test Price
2,800 AED✅ Home Collection Available
COL11A2 Gene Deafness, Autosomal Dominant Type 13 (DFNA13) Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance by Consultant Medical Geneticist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
This advanced Next‑Generation Sequencing (NGS) test deciphers the entire coding region of the COL11A2 gene to confirm autosomal dominant nonsyndromic hearing loss type DFNA13, with 99.9% diagnostic accuracy under DHA standards and UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection. The price is 2800 AED all-inclusive.
Test Overview & Methodology
This advanced Next‑Generation Sequencing (NGS) test deciphers the entire coding region of the COL11A2 gene to confirm autosomal dominant nonsyndromic hearing loss type DFNA13. The test uses state-of-the-art sequencing technology with ≥100x coverage ensuring high-resolution variant calling including point mutations, indels, and copy number variations (CNV via complementary MLPA if indicated).
| Feature | Our COL11A2 NGS Test | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Technology | Next‑Generation Sequencing (NGS) | Sanger Sequencing (single amplicon) |
| Variant Coverage | Full gene – point mutations, indels, copy number variations* | Limited to known hotspot regions; misses large rearrangements |
| Turnaround Time | 3 to 4 Weeks | 6–8 Weeks (if full gene walk required) |
| Sensitivity | 99.9% | ~95% for point mutations only |
| Cost (UAE) | 2800 AED | ~1500–2000 AED per exon (full gene significantly higher) |
*CNV detection via complementary MLPA if indicated; NGS coverage ≥100x ensures high-resolution variant calling.
Physician Insight & Safety Protocols
“A definitive molecular diagnosis of DFNA13 through COL11A2 sequencing is a crucial step, but it is only the beginning. I emphasize the importance of integrating genetic findings with serial audiological evaluations and ENT assessments to personalize hearing rehabilitation—whether through hearing aids, cochlear implants, or educational interventions. Each family’s journey is unique, and ongoing clinical correlation remains essential.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication & Clinical Advisory
⚠️ Do not discontinue prescribed medication without consulting your doctor. Genetic test outcomes must be evaluated in the context of your full treatment plan. This test does not replace ongoing medical management.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria
- Minors without parental/guardian consent (per Federal Decree-Law No. 4 of 2016 on Medical Liability).
- Inability to provide valid informed consent (cognitive impairment, language barrier without interpreter).
- Acute systemic illness or severe anemia that precludes safe phlebotomy.
ER Red Flags – Seek Immediate Care
- Sudden, rapid worsening of hearing loss in either ear.
- New-onset severe vertigo, tinnitus, or loss of balance.
- Focal neurological signs (facial weakness, dysarthria).
If you experience any of these, please visit the nearest Emergency Department. This test is not a substitute for urgent ENT evaluation.
Patient FAQ & Clinical Guidance
1. What is the COL11A2 genetic test and who should consider it?
Direct answer: This NGS test analyzes the COL11A2 gene to diagnose autosomal dominant hearing loss type DFNA13, recommended for individuals with progressive sensorineural hearing loss and a family history of deafness.
Ideal candidates include adults and children with bilateral, non‑syndromic hearing loss that began in childhood or adulthood, and families seeking genetic confirmation to guide treatment, family planning, or cascade screening of relatives. A pre‑test genetic counselling session is highly advised to discuss implications.
2. How accurate is the COL11A2 NGS test and how long do results take?
Direct answer: The test boasts 99.9% analytical sensitivity and specificity, with results delivered in 3 to 4 weeks via our secure patient portal.
All variants are confirmed by orthogonal methods and interpreted according to ACMG/AMP guidelines. The report includes a clear classification (pathogenic, likely pathogenic, VUS, benign) and clinical correlation notes. A follow‑up telephonic consultation is included to help you understand the findings.
3. Does insurance cover this in the UAE, and what are the payment options?
Direct answer: We offer direct insurance billing verification via WhatsApp at +971 54 548 8731 for major UAE insurers, and accept self‑pay at 2800 AED with transparent, all‑inclusive pricing.
Prior authorization can be obtained for plans covering genetic diagnostic testing. For uninsured or self‑pay patients, we provide flexible payment links and a detailed invoice suitable for reimbursement claims. Please contact our patient support team to confirm coverage or to request a home collection.
UAE Regulatory & Data Privacy Adherence
100% UAE Regulatory Compliance
This service strictly adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Data privacy is ensured under the UAE Personal Data Protection Law. Processing laboratory holds ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and DHA Facility License No. 1143. All testing is performed at Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE under the brand DNA Labs UAE.
Clinical & Logistical Metadata
| Test Name | COL11A2 Gene Deafness, Autosomal Dominant Type 13 (DFNA13) Genetic Test |
| Price (AED) | 2800 |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection Available (8 AM – 11 PM daily) |
| Methodology Used | Next-Generation Sequencing (NGS), ≥100x coverage; complementary MLPA for CNV detection if indicated |
| ICD-10-CM Code | H90.5 |
| LOINC Code | 95156-8 |
| DHA Facility License & Laboratory Address | DHA License No. 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians